Noticias y vídeos - ABIVAX - Inglés - Página 2

Abivax Provides Update on Ulcerative Colitis (UC) Combination Therapy Program Strategy and Announces Early Preclinical Combination Data of Obefazimod and Etrasimod in Inflammatory Bowel Disease (IBD) Mouse Model Abivax is actively conducting preclinical studies with multiple oral and injectable therapies and will report additional data in Q4 2024. Pre-clinical evaluation of obefazimod combined with etrasimod improved body weight protection and Disease Activity Index with a synergistic and...

EQS-News: ABIVAX / Key word(s): Half Year Results Abivax presents first-half 2024 financial results 09.09.2024 / 22:01 CET/CEST The issuer is solely responsible for the content of this announcement. Abivax presents first-half 2024 financial results Cash balance of EUR 222M at June 30, 2024; cash runway in to Q4 2025 PARIS, France, September 9, 2024, 10:00 p.m. CEST – Abivax SA (Euronext Paris: FR0012333284 – ABVX) (“Abivax” or the “Company”), a clinical-stage biotechnology company...

Abivax presents first-half 2024 financial results Cash balance of EUR 222M at June 30, 2024; cash runway in to Q4 2025 PARIS, France, September 9, 2024, 10:00 p.m. CEST – Abivax SA (Euronext Paris: FR0012333284 – ABVX) (“Abivax” or the “Company”), a clinical-stage biotechnology company focused on developing therapeutics that harness the body’s natural regulatory mechanisms to modulate the inflammatory response in patients with chronic inflammatory diseases, announces today its 2024...

EQS-News: ABIVAX / Key word(s): Study Abivax Announces ABTECT Phase 3 Trial Achieves Key Enrollment Milestone 06.08.2024 / 08:30 CET/CEST The issuer is solely responsible for the content of this announcement. Abivax Announces ABTECT Phase 3 Trial Achieves Key Enrollment Milestone Phase 3 ABTECT Trial evaluating obefazimod in moderately to severely active ulcerative colitis (UC) surpassed the 600-patient enrollment milestone confirming ABTECT currently on pace to reach full enrollment in early Q1...

Abivax Announces ABTECT Phase 3 Trial Achieves Key Enrollment Milestone Phase 3 ABTECT Trial evaluating obefazimod in moderately to severely active ulcerative colitis (UC) surpassed the 600-patient enrollment milestone confirming ABTECT currently on pace to reach full enrollment in early Q1 2025 To date, baseline participants baseline characteristics and trial trends in line with observations from Phase 2b trial PARIS, France, August 6, 2024, 8:30 a.m. CEST – Abivax SA (Euronext Paris &...

EQS-News: ABIVAX / Key word(s): Miscellaneous Abivax Provides Operational and Key Program Update 15.07.2024 / 22:00 CET/CEST The issuer is solely responsible for the content of this announcement. Abivax Provides Operational and Key Program Update Phase 3 ABTECT Trial evaluating obefazimod in moderately to severely active ulcerative colitis (UC) on track to complete enrollment in early Q1 2025 Top-line results from the ABTECT 8-week induction trial expected early Q2 2025, with 44-week maintenance...

Abivax Provides Operational and Key Program Update Phase 3 ABTECT Trial evaluating obefazimod in moderately to severely active ulcerative colitis (UC) on track to complete enrollment in early Q1 2025 Top-line results from the ABTECT 8-week induction trial expected early Q2 2025, with 44-week maintenance data on pace to read out in Q1 2026; timing assumptions for New Drug Application (NDA) submission remain unchanged Continued progress on pre-clinical combination therapy program Sylvie Grégoire...

PARIS, France, June 4, 2024 – Abivax SA (Euronext Paris & Nasdaq: ABVX) (“ Abivax ” or the “ Company ”), a clinical-stage biotechnology company focused on developing therapeutics that harness the body’s natural regulatory mechanisms to stabilize the immune response in patients with chronic inflammatory diseases, held its ordinary and extraordinary general meeting of shareholders on May 30, 2024 (the “ General Meeting ”), which was chaired by Mr. Marc de Garidel, CEO and Chairman...

ABIVAX Abivax announces presentation of four abstracts for obefazimod in ulcerative colitis and preclinical colon cancer model at Digestive Disease Week 2024 08-May-2024 / 08:30 CET/CEST Dissemination of a French Regulatory News, transmitted by EQS Group. The issuer is solely responsible for the content of this announcement. Abivax announces presentation of four abstracts for obefazimod in ulcerative colitis and preclinical colon cancer model at Digestive Disease Week 2024 PARIS, France, May 8,...

ABIVAX Abivax annual ordinary and extraordinary general meeting of May 30, 2024 - Availability of the preparatory documents 07-May-2024 / 22:00 CET/CEST Dissemination of a French Regulatory News, transmitted by EQS Group. The issuer is solely responsible for the content of this announcement. Annual ordinary and extraordinary general meeting of May 30, 2024 Availability of the preparatory documents PARIS, France, May 7, 2024, 10:00PM CEST – Abivax SA (Euronext Paris & Nasdaq: ABVX) (“ Abivax...

EQS-News: ABIVAX / Key word(s): Annual Report Abivax publishes financial reports with the French and U.S. securities regulatory agencies 05.04.2024 / 22:00 CET/CEST The issuer is solely responsible for the content of this announcement. Abivax publishes financial reports with the French and U.S. securities regulatory agencies PARIS, France, April 5, 2024, 10:00 p.m. CEST – Abivax SA (Euronext Paris & Nasdaq: ABVX) (“Abivax” or the “Company”), a clinical-stage biotechnology company...

EQS-News: ABIVAX / Key word(s): Annual Results Abivax reports 2023 financial results and operational update 02.04.2024 / 08:30 CET/CEST The issuer is solely responsible for the content of this announcement. Abivax reports 2023 financial results and operational update Raised EUR 500M in 2023, including a EUR 130M capital increase, two structured debt financing transactions aggregating EUR 150M and EUR 223.3M initial public offering on the Nasdaq Global Market Sufficient funds to finance...

EQS-News: ABIVAX / Key word(s): Conference Abivax announces presentation of four abstracts for obefazimod in ulcerative colitis and sponsorship of scientific symposium at the 19th Congress of European Crohn’s and Colitis Organization (ECCO) 13.02.2024 / 08:30 CET/CEST The issuer is solely responsible for the content of this announcement. Abivax announces presentation of four abstracts for obefazimod in ulcerative colitis and sponsorship of scientific symposium at the 19th Congress of European...

PARIS, FRANCE / ACCESSWIRE / February 13, 2024 / Abivax SA (Euronext Paris:ABVX))(NASDAQ:ABVX) ("Abivax" or the "Company"), a clinical-stage biotechnology company focused on developing therapeutics that harness the body's natural regulatory mechanisms to stabilize the immune response in patients with chronic inflammatory diseases, today announced that four scientific abstracts on its lead drug candidate, obefazimod for the treatment of moderately to severely active ulcerative colitis (UC), will...

EQS-News: ABIVAX / Key word(s): Personnel Abivax appoints Ana Sharma as Vice President, Global Head of Quality 07.02.2024 / 08:30 CET/CEST The issuer is solely responsible for the content of this announcement. Abivax appoints Ana Sharma as Vice President, Global Head of Quality PARIS, France, February 7, 2024, 8:30 a.m. CET – Abivax SA (Euronext Paris and Nasdaq: ABVX) (“Abivax” or the “Company”), a clinical-stage biotechnology company focused on developing therapeutics that harness...

EQS-News: ABIVAX / Key word(s): Study Abivax announces update to obefazimod Phase 2b clinical development program in moderately to severely active Crohn’s disease 02.02.2024 / 08:30 CET/CEST The issuer is solely responsible for the content of this announcement. Abivax announces update to obefazimod Phase 2b clinical development program in moderately to severely active Crohn’s disease Obefazimod Crohn’s Disease (CD) IND filed with the FDA in December 2023 and cleared to proceed In alignment...

EQS-News: ABIVAX / Key word(s): Conference Abivax to host KOL Investor Event to review phase 2b clinical data and phase 3 trial design for obefazimod in patients with moderately to severely active ulcerative colitis on February 6, 2024 24.01.2024 / 08:30 CET/CEST The issuer is solely responsible for the content of this announcement. Abivax to host KOL Investor Event to review phase 2b clinical data and phase 3 trial design for obefazimod in patients with moderately to severely active ulcerative...

EQS-News: ABIVAX / Key word(s): Miscellaneous Abivax provides 2024 strategic outlook and lays out key milestones over next 12 months 22.01.2024 / 08:30 CET/CEST The issuer is solely responsible for the content of this announcement. Abivax provides 2024 strategic outlook and lays out key milestones over next 12 months Induction data read-out expected Q1 2025 from the pivotal Phase 3 ABTECT program evaluating obefazimod in moderately to severely active ulcerative colitis (UC) Formal process...

EQS-News: ABIVAX / Key word(s): Miscellaneous Abivax 2024 Financial Communication Calendar 04.01.2024 / 08:30 CET/CEST The issuer is solely responsible for the content of this announcement. Abivax 2024 Financial Communication Calendar PARIS, France, January 4, 2024, 8:30 a.m. CET – Abivax SA (Euronext Paris & Nasdaq: ABVX) (“Abivax” or the “Company”), a clinical-stage biotechnology company focused on developing therapeutics that harness the body’s natural regulatory mechanisms to...

EQS-News: ABIVAX / Key word(s): Miscellaneous Abivax announces the resumption of its liquidity contract 21.11.2023 / 08:30 CET/CEST The issuer is solely responsible for the content of this announcement. Abivax announces the resumption of its liquidity contract Paris, France, November 21, 2023 – 8:30 a.m. CET – Abivax SA (Euronext Paris and Nasdaq: ABVX) (“ Abivax ” or the “ Company ”), a clinical-stage biotechnology company focused on developing therapeutics that harness the body’s...